Orforglipron

Yes, FDA-approved oral GLP-1 tablets (such as Wegovy and Foundayo) work effectively for weight loss, producing results comparable to injections, though injections still hold a modest edge in clinical data[1][8]. Key Comparisons Between Oral Tablets and Injections: Feature Oral Tablets (FDA-Approved) Injectable GLP-1s Weight Loss ~12–14% of body weight (e.g., Wegovy 25 mg: 13.6%; Orforglipron: ~14%)[1][6] ~15–20% of body weight (slightly higher in trials)[1][4] Mechanism Mimics hormone to slow digestion, increase fullness, and suppress appetite[1][8] Same mechanism; bypasses digestion for direct absorption[1] Side Effects Gastrointestinal issues (nausea, vomiting, diarrhea) occur at similar rates to injections[1][6] Similar gastrointestinal side effects[1] Bioavailability Low (0.4%–1%) due to stomach acid breakdown, but new formulations improve absorption[1][8] High and consistent absorption[8] Convenience No needles; preferred for those averse to self-injection[1][2] Requires injection; may be less convenient for some Crucial Warning on Compounded Drops and Sublingual Versions: Compounded GLP-1 drops, sublingual semaglutide, and tirzepatide patches generally do not work and are not proven effective[3]. No Human Evidence: There are no published human studies demonstrating that sublingual drops produce meaningful weight loss[3]. Rat Study Only: The only existing study was conducted on rats and explicitly states it cannot guide human dosing[3]. Safety & Quality Risks: The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing; these formulations often lack the absorption technology found in FDA-approved medications[3][7]. Expert Recommendation: Health experts recommend FDA-approved oral GLP-1s (like Wegovy or Orforglipron) because they have been tested in large clinical trials, whereas compounded products have unproven efficacy[3][6]. Brands to Consider (FDA-Approved): Wegovy (oral semaglutide): Approved by the FDA in January 2025 for obesity treatment; delivered as a daily pill[1]. Foundayo (oral orforglipron): Approved recently by the FDA; a daily pill by Eli Lilly showing ~12% weight loss[1][6]. If you are considering oral GLP-1s, choose FDA-approved tablets (Wegovy or Foundayo) rather than compounded drops, as they offer proven efficacy and safety[1][6]. Injections may still provide slightly better results for some, but the difference is small for most people[1].

Mentioned in position 3 of 3